Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1470-2045(24)00092-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dose-dependent Efficacy of Olanzapine for Chemotherapy-induced Nausea and Vomiting: A Systematic Review and Meta-analysis.
Anticancer Res
September 2025
Department of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan
Background/aim: This study aimed to investigate the efficacy of olanzapine, an antiemetic agent used to prevent chemotherapy-induced nausea and vomiting (CINV), at 5 and 10 mg/day, by chemotherapy emetogenic risk, and to evaluate the efficacy of low dose olanzapine at 2.5 mg/day.
Materials And Methods: PubMed and Web of Science were searched to identify studies evaluating the efficacy of olanzapine in CINV prevention from database inception up to August 31, 2023.
Efficacy of intensive antiemetic therapy including olanzapine in multiple myeloma patients treated with high-dose melphalan with autologous stem cell transplantation.
Support Care Cancer
August 2025
Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Purpose: Conditioning with high-dose melphalan (MEL) followed by autologous stem cell transplantation (ASCT) is the standard treatment for multiple myeloma (MM). The optimal regimen to prevent chemotherapy-induced nausea and vomiting (CINV) is unclear. We aimed to retrospectively evaluate the antiemetic effect and safety of a four-drug intensive regimen including olanzapine (OLA) on CINV in MM patients receiving MEL/ASCT.
View Article and Find Full Text PDFRandomized, double-blind phase III trial of a dexamethasone-free regimen for managing highly emetogenic chemotherapy-induced nausea and vomiting.
Int J Cancer
July 2025
Department of Biotherapy, Cancer Center, West China Hospital & State Key Laboratory of Biotherapy, Sichuan University, Chengdu, China.
Chemotherapy-induced nausea and vomiting (CINV) remains a prevalent treatment complication, often significantly impairing patients' quality of life and reducing adherence to chemotherapy regimens. The standard triplet antiemetic regimen, including either a neurokinin-1 (NK1) receptor antagonist (RA) or olanzapine, combined with a 5-hydroxytryptamine type 3 (5-HT3) RA and dexamethasone (DEX), faces challenges primarily due to DEX-related adverse effects and its potential to compromise the efficacy of antitumor agents. This study assessed whether omitting DEX (F-Group: olanzapine + 5-HT3 RA) is non-inferior to the standard D-Group (olanzapine + 5-HT3 RA + DEX).
View Article and Find Full Text PDFEfficacy of NEPA for prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic chemotherapy and usefulness of adding olanzapine for grade 2 or higher emesis.
Medicine (Baltimore)
July 2025
Department of Internal Medicine, Medical Oncology and Hematology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.
NEPA has demonstrated superiority in preventing chemotherapy-induced nausea and vomiting (CINV) compared to palonestron and non-inferiority compared to aprepitant/granisetron. However, despite the application of NEPA in previous studies, grade (Gr) 2 or higher CINV was reported in 20% to 30% of cases. The aim of this study was to investigate the efficacy of NEPA for CINV prevention in Korean cancer patients treated with highly emetogenic chemotherapy (HEC), and to evaluate the usefulness of adding olanzapine in cases experiencing Gr 2 or higher CINV in previous cycles.
View Article and Find Full Text PDFAprepitant versus Olanzapine in Patients of Breast Cancer on Adriamycin and Cyclophosphamide Regimen - Role in Effectiveness of Prevention of Nausea and Vomiting.
Acta Med Litu
February 2025
Department of Pharmacology, AIIMS Guwahati, Changsari, Assam, India.
Background: Chemotherapy-induced nausea and vomiting (CINV) is a significant concern for patients undergoing highly emetogenic chemotherapy (HEC). This study compares the efficacy of aprepitant and olanzapine in preventing CINV in breast cancer patients receiving Adriamycin and Cyclophosphamide (AC).
Methods: A prospective, comparative, observational study was conducted over one year at the State Cancer Institute, Guwahati, India.